Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells

Cancer Research

Volumn 58, Issue 14, 1998, Pages 2965-2968

  Morse, Michael A ^a   Lyerly, H Kim ^a   Gilboa, Eli ^a   Thomas, Elaine ^b   Nair, Smita K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; RNA; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIGENS, CD40; CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; DENDRITIC CELLS; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 0032527908     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
2. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
3. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
4. Nair, S. K., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Int. J. Cancer, 70: 706-715, 1997.
5. Bender, A., Sapp, M., Schuler, G., Steinman, R. M., and Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods, 196: 121-135, 1996.
6. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D, and Schuler, G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods, 190: 137-151, 1996.
7. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P., Steinman, R., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
8. Morse, M. A., Zhou, L. J., Tedder, T. F., Lyerly, H. K., and Smith, C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann. Surg., 226: 6-16, 1997.
9. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., and Banchereau, J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med., 180: 1263-1272, 1994.
10. Ludewig, B., Graf, D., Gelderbloom, H. R., Becker, Y., Kroczek, R. A., and Pauli, G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-α, but strongly enhanced by interleukin-10. Eur. J. Immunol., 25: 1943-1950, 1995.
11. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.
12. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and down regulation by IL-4 and IL-10. J. Exp. Med., 184: 741-746, 1996.
13. Wong, C., Morse, M., and Nair, S. K. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunother., 21: 32-40, 1998.
14. Boczkowski, D., Nair, S., Snyder, D., and Gilboa, E. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
15. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., and Gilboa, E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotech., 16: 1-8, 1998.
16. Gabrilovich, D. I., Chen, H. L., Girgis, K., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 10: 1096-1103, 1996.
17. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med., 182: 389-400, 1995.
18. Lanzavecchia, A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol., 8: 348-354, 1996.
19. Koch, F., Trockenbacher, B., Kämpgen, E., Grauer, O., Stössel, H., Livingstone, A. M., Schuler, G., and Romani, N. Antigen processing in populations of mature murine dendritic cells is caused by subsets of incompletely matured cells. J. Immunol., 155: 93-100, 1995.
20. McLellan, A. D., Sorg, R. V., Williams, L. A., and Hart, D. N. J. Human dendritic cells activate T lymphocytes via CD40:CD40 ligand-dependent pathway. Eur. J. Immunol., 26: 1204-1210, 1996.